Total medical devices industry M&A deals worth $28.2bn were announced in North America in November 2022, led by Johnson & Johnson’s $16.6bn acquisition of Abiomed, according to GlobalData’s deals database.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

The value marked an increase of 22112.6% over the previous month of $127m and a rise of 355.7% when compared with the last 12-month average of $6.19bn.

North America held a 100.00% share of the global medical devices industry M&A deal value that totalled $28.21bn in November 2022. With a 100.00% share and deals worth $28.21bn, the US was the top country in North America’s M&A deal value across medical devices industry.

In terms of M&A deal activity, North America recorded 31 deals during November 2022, marking an increase of 29.17% over the previous month and a rise of 10.71% over the 12-month average. The US recorded 26 deals during the month.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

North America medical devices industry M&A deals in November 2022: Top deals

The top five medical devices industry M&A deals accounted for 99.9% of the overall value during November 2022.

The combined value of the top five medical devices deals stood at $28.19bn, against the overall value of $28.2bn recorded for the month.

The top five medical devices industry M&A deals of November 2022 tracked by GlobalData were:

1) Johnson & Johnson’s $16.6bn acquisition deal with Abiomed

2) The $8.9bn acquisition of Summit Health by VillageMD

3) WerfenLife’s $2bn acquisition deal with Immucor

4) The $615m acquisition of Apollo Endosurgery by Boston Scientific

5) Myriad Genetics’s $75m acquisition deal with Gateway Genomics